EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 553 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR New Approach Uses Much Less Tissue to Analyze Tumor Proteins and... February 27, 2020 FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer... January 10, 2025 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Cancer-impacted mother becomes Times Square billboard to help child come across... July 21, 2023 Load more HOT NEWS Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation FDA Approves Crizotinib for Children and Young Adults with Relapsed or... FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ
